上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
12期
13-14,36
,共3页
骨肉瘤%新辅助化疗%坏死率%预测%基因芯片
骨肉瘤%新輔助化療%壞死率%預測%基因芯片
골육류%신보조화료%배사솔%예측%기인심편
osteosarcoma%neoadjuvant chemotherapy%necrosis rate%gene chip
骨肉瘤在新辅助化疗后的原发灶肿瘤组织坏死率对于患者的预后具有决定性意义，寻找有效的检测手段或检测指标在手术前预测化疗疗效，并在术前及时调整治疗显得尤为重要。本文综述基因芯片对骨肉瘤新辅助化疗疗效的预测作用。
骨肉瘤在新輔助化療後的原髮竈腫瘤組織壞死率對于患者的預後具有決定性意義，尋找有效的檢測手段或檢測指標在手術前預測化療療效，併在術前及時調整治療顯得尤為重要。本文綜述基因芯片對骨肉瘤新輔助化療療效的預測作用。
골육류재신보조화료후적원발조종류조직배사솔대우환자적예후구유결정성의의，심조유효적검측수단혹검측지표재수술전예측화료료효，병재술전급시조정치료현득우위중요。본문종술기인심편대골육류신보조화료료효적예측작용。
Histological response or tumor necrosis rate to neoadjuvant chemotherapy has been shown to be associated with survival in osteosarcoma patients. Accurate and noninvasive detective methods to predict response to neoadjuvant chemotherapy would be important for planning surgery and adjustment subsequent therapy. This review summarizes recent advances in predicting response to neoadjuvant chemotherapy for osteosarcoma by gene-expression proifles.
